Labcorp Unveils Commercial Blood Test for GFAP

Labcorp (Burlington, NC) announced the launch of a first-of-its-kind commercial blood test in the United States that measures the biomarker glial fibrillary acidic protein (GFAP), which is released into the bloodstream when astrocytes are damaged. This test offers physicians a way to assess the presence and progression of a variety of conditions including Alzheimer disease (AD), multiple sclerosis (MS), glioblastoma, and traumatic brain injury (TBI). Unlike traditional methods that rely on complex imaging or invasive procedures, the GFAP test can be performed through a simple blood draw in a variety of settings, including physician offices, hospitals, or Labcorp laboratory service centers.

"The introduction of the GFAP biomarker test marks a significant milestone for Labcorp and the field of neurodegenerative disease diagnostics," said a company spokesperson. "This test has the potential to revolutionize the way we detect and monitor these debilitating conditions, ultimately leading to better patient outcomes."